23 August 2016
Ellex to Host Lunch Symposium on ABiC at ESCRS 2016
Ellex Medical will host a lunch symposium (Eurotimes Satellite Education Program), on ABiC™ for the treatment of primary open-angle glaucoma at the Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) being held 10-14 September 2016 at the Bella Center, Copenhagen, Denmark.
The symposium, to be held on Sunday, 11 September from 1:00-2:00 pm in Room B8, will feature presentations by Mahmoud A. Khaimi, MD, (Dean McGee Eye Institute, University of Oklahoma) and Mark J. Gallardo, MD (El Paso Eye Surgeons, Texas), and will be moderated by Norbert Koerber, PhD, MD (Augencentrum Köln-Porz, Germany). Drs Gallardo and Khaimi will share their 12-month findings in 228 eyes with mild-to-moderate primary open-angle glaucoma (POAG) who underwent ABiC™ either alone or in combination with cataract surgery. Dr Khaimi will also share his 3-year results with traditional canaloplasty, including no suture data.
ABiC™ is a new ab-interno MIGS procedure that uses Ellex’s proprietary iTrack™ 250-micron microcatheter to circumferentially viscodilate Schlemm’s canal, the collector channels and the trabecular meshwork in order to restore natural aqueous outflow. Thus ABiC™ addresses all aspects of outflow resistance. In contrast, other minimally-invasive glaucoma surgery (MIGS) procedures typically treat only one aspect of aqueous outflow.
During the ab-interno MIGS procedure, ABiC™ utilizes a process of viscodilation of Schlemm’s canal to flush out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt – achieving an average reduction in mean IOP of 30%, combined with a 50% reduction in medication burden. One of the challenges associated with glaucoma and its treatment is that the location of increased aqueous outflow resistance – and how this resistance is generated – is unclear. If a glaucoma surgeon were to remove the site(s) where increased outflow resistance resides, IOP would fall. However, if it is not possible to identify the site(s) of increased outflow resistance in a specific POAG eye, it is difficult to determine which parts of the outflow system are more relevant than others in terms of lowering IOP. Consequently, it is important to address all aspects of the ocular outflow system.
Meet the Experts
Ellex will also host in-booth “Meet the Expert” sessions to encourage peer-to-peer exchange. These will take place on Saturday, 10 September through Monday 12 September. On each day from 3:00-4:00 pm, Professor Koerber and Drs Gallardo and Khaimi will be at Ellex Exhibit #C216, where they will be available to share their experience with ABiC and also offer surgical pearls for success. In addition, Drs Gallardo and Khaimi will be available for interview regarding their experiences with ABiC™ during ESCRS 2016. To make an appointment, please email: email@example.com
Ellex Medical (Ellex) is a pioneer in the development of medical technologies for the diagnosis and treatment of eye disease. With more than 20,000 systems delivered to market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, France, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products. On 31 December 2013 Ellex acquired the Canaloplasty microcatheterbased glaucoma surgical treatment from iScience Interventional, Inc.
For additional information about Ellex and its products, please visit www.ellex.com